- |||||||||| evodenoson (ATL313) / AbbVie, namodenoson (CF102) - Can / Fite
Adenosine Receptors Differentially Mediate Enteric Glial Cell Death And Proinflammatory Response Induced By Clostridioides Difficile Toxins A And B (Exhibit and Poster Hall) - Jun 4, 2022 - Abstract #ASMMicrobe2022ASM_Microbe_3136;
A2A agonist (ATL313), but not A2A antagonist (SCH58261), decreased (p<0.001) apoptosis as detected by the formation of Phosphatidylserine-annexin binding and caspase 3/7 activity induced by TcdA and TcdB in EGCs...A3 agonist (Cl-IBMECA), but not A3 blocker (MRS1220), reduced apoptosis in EGCs challenged with TcdA and TcdB...In vivo, infected A2B KO mice, but not A2A, exhibited a lower percentage of S100B+TUNEL+cells compared to infected WT mice (p<0.0001). Our findings indicate that EGCs elicit a protective anti-inflammatory, via activation of A2A, A2B and A3, and anti-apoptotic, via upregulation of A2A and A3 and downregulation of A2B, responses against C. difficile toxins.
- |||||||||| evodenoson (ATL313) / Allergan, CGS 21680 / Tocris
Journal: Sustained Reversal of Central Neuropathic Pain Induced by a Single Intrathecal Injection of Adenosine A2A Receptor Agonists. (Pubmed Central) - Apr 26, 2019
A second A2AR agonist, 4-(3-(6-amino-9-(5-cyclopropylcarbamoyl-3,4-dihydroxytetrahydrofuran-2-yl)-9H-purin-2-yl)prop-2-ynyl)piperidine-1-carboxylic acid methyl ester (ATL313), was also able to significantly prevent and reverse SCI-induced allodynia for several weeks after a single intrathecal injection, providing converging lines of evidence of A2AR involvement. The enduring pain reversal after a single intrathecal injection of A2AR agonists suggests that A2AR agonists could be exciting new candidates for treating SCI-induced central neuropathic pain.
- |||||||||| evodenoson (ATL313) / AbbVie
Trial completion: Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Feb 9, 2012
P1/2, N=147, Completed,
The enduring pain reversal after a single intrathecal injection of A2AR agonists suggests that A2AR agonists could be exciting new candidates for treating SCI-induced central neuropathic pain. Recruiting --> Completed
|
